ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer
ASH2L promotes tamoxifen resistance and CSC activity through ITGA6/ERK signalling. Combination therapy with tamoxifen and an ERK inhibitor may be a promising strategy for ER-positive breast cancer patients with ASH2L overexpression.
Authors
- Young-Hyeon Kye
- Sojeong Moon
- Gu Sheng Kong
- Jae-Kyung Myung
- Tack-Hoon Kim
- Hea-Ry Cha
- Jeong-Yun Eom
Institutions
- Hanyang University Seoul Hospital (KR)
- Hanyang University (KR)
- Korea Institute of Science and Technology (KR)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1038/s41416-026-03347-8
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Research Foundation
- Korea Health Industry Development Institute
- National Research Foundation of Korea